A Phase II, Single-arm, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sulfatinib as a Second-line Treatment in Patients With Surgically Unresectable or Metastatic Biliary Tract Carcinoma

Trial Profile

A Phase II, Single-arm, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sulfatinib as a Second-line Treatment in Patients With Surgically Unresectable or Metastatic Biliary Tract Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Sulfatinib (Primary)
  • Indications Biliary cancer
  • Focus Therapeutic Use
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 09 Jan 2017 According to a Chi-Med media release, first drug dose was administered in this trial.
    • 09 Jan 2017 Status changed from not yet recruiting to recruiting.
    • 22 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top